ABIVAX · ISIN: FR0012333284 · EQS - Company News

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the first patient was enr...

EURONEXT:ABVX Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News ABIVAX

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
03 October 2024 10:01PM
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
FR0012333284
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s na...
ABIVAX
About the publication
03 October 2024 08:30AM
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
FR0012333284
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated with a de-escalated dose of 25 mg of obefazimod once daily demonstrated maintenance of clinical remission at weeks 48 and 96 Efficacy and safety demo...
ABIVAX
About the publication
26 September 2024 08:30AM
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
FR0012333284
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative col...
ABIVAX
About the publication
25 September 2024 10:01PM
Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
FR0012333284
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model Abivax is actively conducting preclinical studies with multiple oral and injectable therapies and will report additional data in Q4 2024....
ABIVAX
About the publication
09 September 2024 10:01PM
Abivax presents first-half 2024 financial results
FR0012333284
Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s nat...
ABIVAX
About the publication
02 April 2024 08:30AM
Abivax reports 2023 financial results and operational update
FR0012333284
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global Market Sufficient funds to finance operations into Q4 2025, including through the announcement of t...
ABIVAX
About the publication
13 February 2024 08:30AM
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
FR0012333284
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) PARIS, France, February 13, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechno...
ABIVAX
About the publication
07 February 2024 08:30AM
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
FR0012333284
Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune respon...
ABIVAX
About the publication
02 February 2024 08:30AM
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
FR0012333284
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December 2023 and cleared to proceed In alignment with FDA feedback, Abivax to modify CD trial design and conduct dose ranging Phase 2b clinical trial Start of pati...
ABIVAX
About the publication
24 January 2024 08:30AM
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
FR0012333284
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS, France, January 24, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology c...
ABIVAX
About the publication
22 January 2024 08:30AM
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
FR0012333284
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC) Formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC h...
ABIVAX
About the publication
04 January 2024 08:30AM
Abivax 2024 Financial Communication Calendar
FR0012333284
Abivax 2024 Financial Communication Calendar PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chro...
ABIVAX
About the publication
21 November 2023 08:30AM
Abivax announces the resumption of its liquidity contract
FR0012333284
Abivax announces the resumption of its liquidity contract Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in pati...
ABIVAX
About the publication
14 November 2023 02:00PM
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
FR0012333284
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the imm...
ABIVAX
About the publication
24 October 2023 10:05PM
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
FR0012333284
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market PARIS, France, October 24, 2023 – 10:05 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to mod...
ABIVAX
About the publication
20 October 2023 03:45PM
Abivax announces trading resumption of its ordinary shares on Euronext Paris
FR0012333284
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, October 20, 2023 – 03:45 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate t...
ABIVAX
About the publication
20 October 2023 03:00PM
Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market 
FR0012333284
Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market  PARIS, France, October 20, 2023 – 3:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to...
ABIVAX
About the publication
20 October 2023 08:45AM
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
FR0012333284
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, October 20, 2023 – 08:45 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modula...
ABIVAX
About the publication
19 October 2023 12:00AM
Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
FR0012333284
Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range PARIS, France, October 18, 2023 – 11:55 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the bo...
ABIVAX
About the publication
16 October 2023 05:40PM
Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
FR0012333284
Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing PARIS, France, October 16, 2023 – 05:40 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulato...
ABIVAX
About the publication
02 October 2023 06:00PM
Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
FR0012333284
Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023 Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC) Moderated poster presentation highlighting correlation of pharmacok...
ABIVAX
About the publication
29 September 2023 11:00PM
Abivax files registration statement for proposed initial public offering in the United States
FR0012333284
Abivax files registration statement for proposed initial public offering in the United States PARIS, France, September 29, 2023 – 11:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mecha...
ABIVAX
About the publication
29 September 2023 06:00PM
Abivax announces the release of its 2023 half-year financial report
FR0012333284
Abivax announces the release of its 2023 half-year financial report  PARIS, France, September 29, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immu...
ABIVAX
About the publication
21 September 2023 06:00PM
Abivax presents first-half 2023 financial results
FR0012333284
Abivax presents first-half 2023 financial results PARIS, France, September 21, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in pati...
ABIVAX
About the publication
07 September 2023 08:00AM
Abivax provides business and operational update
FR0012333284
Abivax provides business and operational update ABTECT Phase 3 Global Clinical Trial Enrollment Progressing as Planned; Induction and Maintenance Data Readouts Expected in Q1 2025 and Q1 2026, Respectively Durability of Efficacy Results with No New Safety Signals Observed in Step-Down Dosing from 50 mg to 25 mg for Approximately the Third and Fif...
ABIVAX
About the publication
23 August 2023 06:00PM
Abivax appoints Patrick Malloy as Senior Vice President Investor Relations
FR0012333284
Abivax appoints Patrick Malloy as Senior Vice President Investor Relations PARIS, France, August 23, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”) today announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations. Mr. Malloy brings 20 years of investor relatio...
ABIVAX
About the publication
21 August 2023 08:00AM
Abivax secures up to EUR 150M from two structured debt financing transactions
FR0012333284
Abivax secures up to EUR 150M from two structured debt financing transactions Up to EUR 75M from Kreos Capital and Claret European Growth Capital Up to EUR 75M from Heights Capital Management EUR 27M of additional cash resources for Abivax at drawdown of the first tranches PARIS, France, August 21, 2023, 8:00 a.m. CEST – Abivax SA (Euronext Par...
ABIVAX
About the publication
10 August 2023 06:00PM
Abivax announces plans to conduct registered public offering in the United States
FR0012333284
Abivax announces plans to conduct registered public offering in the United States PARIS, France, August 10, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States, subject...
ABIVAX
About the publication
11 July 2023 06:00PM
Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
FR0012333284
Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors PARIS, France, July 11, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic ...
ABIVAX
About the publication
11 July 2023 06:00PM
Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
FR0012333284
Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors PARIS, France, July 11, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic ...
ABIVAX
About the publication
15 June 2023 10:41PM
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
FR0012333284
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023 The award recognizes a significant capital market transaction in the biotech sector Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors in February 2023 P...
ABIVAX
About the publication
15 June 2023 10:41PM
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
FR0012333284
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023 The award recognizes a significant capital market transaction in the biotech sector Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors in February 2023 P...
ABIVAX
About the publication
08 June 2023 06:00PM
Abivax stock included in MSCI Indexes
FR0012333284
Abivax stock included in MSCI Indexes As of June 1st, the Abivax stock is represented in the MSCI Indexes The MSCI Indexes reflect the evolution of the world’s equity markets to support investors building effective portfolios based on risk and return assessments PARIS, France, June 8, 2023 – 6:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284...
ABIVAX
About the publication
08 June 2023 06:00PM
Abivax stock included in MSCI Indexes
FR0012333284
Abivax stock included in MSCI Indexes As of June 1st, the Abivax stock is represented in the MSCI Indexes The MSCI Indexes reflect the evolution of the world’s equity markets to support investors building effective portfolios based on risk and return assessments PARIS, France, June 8, 2023 – 6:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284...
ABIVAX
About the publication
08 June 2023 04:21PM
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
FR0012333284
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting Shareholders approved all proposed resolutions PARIS, France, June 6, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune syst...
ABIVAX
About the publication
08 June 2023 04:21PM
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
FR0012333284
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting Shareholders approved all proposed resolutions PARIS, France, June 6, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune syst...
ABIVAX
About the publication
08 June 2023 04:20PM
Abivax appoints Ida Hatoum as Chief People Officer
FR0012333284
Abivax appoints Ida Hatoum as Chief People Officer As Chief People Officer of Abivax, Ida Hatoum will be leading the organizational strategy to build and strengthen the Abivax team in the United States and Europe across all functions Ida has a proven track record in talent acquisition and development in the biopharmaceutical industry PARIS, Fran...
ABIVAX
About the publication
08 June 2023 04:20PM
Abivax appoints Ida Hatoum as Chief People Officer
FR0012333284
Abivax appoints Ida Hatoum as Chief People Officer As Chief People Officer of Abivax, Ida Hatoum will be leading the organizational strategy to build and strengthen the Abivax team in the United States and Europe across all functions Ida has a proven track record in talent acquisition and development in the biopharmaceutical industry PARIS, Fran...
ABIVAX
About the publication
15 May 2023 07:00PM
Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
FR0012333284
Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents PARIS, France, May 15, 2023 – 7:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat ...
ABIVAX
About the publication
15 May 2023 07:00PM
Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
FR0012333284
Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents PARIS, France, May 15, 2023 – 7:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat ...
ABIVAX
About the publication
04 May 2023 06:00PM
Abivax publishes Universal Registration Document 2023 “Document d’Enregistrement Universel”
FR0012333284
Abivax publishes Universal Registration Document 2023 “Document d’Enregistrement Universel” PARIS, France, May 4, 2023 – 6:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic in...
ABIVAX
About the publication
04 May 2023 06:00PM
Abivax publishes Universal Registration Document 2023 “Document d’Enregistrement Universel”
FR0012333284
Abivax publishes Universal Registration Document 2023 “Document d’Enregistrement Universel” PARIS, France, May 4, 2023 – 6:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic in...
ABIVAX
About the publication
02 May 2023 06:00PM
Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
FR0012333284
Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients The authors of the expert article published in the Journal of Crohn’s and Colitis include major European and North American Key Opinion Leaders in the field of Inflammatory Bowel Diseases The KOLs state that obefazimod is a fir...
ABIVAX
About the publication
02 May 2023 06:00PM
Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
FR0012333284
Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients The authors of the expert article published in the Journal of Crohn’s and Colitis include major European and North American Key Opinion Leaders in the field of Inflammatory Bowel Diseases The KOLs state that obefazimod is a fir...
ABIVAX
About the publication
19 April 2023 09:00PM
Abivax reports 2022 financial results and operations update
FR0012333284
Abivax reports 2022 financial results and operations update Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to plan Abivax reports promising Phase 2b maintenance results with 52.5% of UC patients in clinical remission after two years of continued oral ...
ABIVAX
About the publication
19 April 2023 09:00PM
Abivax reports 2022 financial results and operations update
FR0012333284
Abivax reports 2022 financial results and operations update Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to plan Abivax reports promising Phase 2b maintenance results with 52.5% of UC patients in clinical remission after two years of continued oral ...
ABIVAX
About the publication
18 April 2023 06:00PM
Abivax appoints Michael Ferguson as Chief Commerical Officer
FR0012333284
Abivax appoints Michael Ferguson as Chief Commercial Officer Michael Ferguson has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically in Inflammatory Bowel Diseases (IBD) As CCO of Abivax, Michael Ferguson will be leadi...
ABIVAX
About the publication
18 April 2023 06:00PM
Abivax appoints Michael Ferguson as Chief Commerical Officer
FR0012333284
Abivax appoints Michael Ferguson as Chief Commercial Officer Michael Ferguson has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically in Inflammatory Bowel Diseases (IBD) As CCO of Abivax, Michael Ferguson will be leadi...
ABIVAX
About the publication
More ABIVAX related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN